What Causes Low Anti-Müllerian Hormone in Women?

What Causes Low Anti-Müllerian Hormone in Women?

Low AMH most commonly reflects a smaller-than-average pool of remaining follicles, which can happen with age, autoimmune conditions, prior ovarian surgery, or chronic oxidative stress — but nutritional gaps and lifestyle factors genuinely move the needle too. The main caveat is that AMH is a snapshot, not a sentence: values fluctuate, and some women with low AMH conceive without intervention. The exception is premature ovarian insufficiency (POI), where decline is steeper and less reversible without medical support.

---

What Is AMH and Why Does It Matter?

Anti-Müllerian hormone is a glycoprotein secreted by granulosa cells surrounding the small antral follicles in your ovaries. Unlike FSH or estradiol, it doesn't swing dramatically across your menstrual cycle, which makes it a reliable marker of ovarian reserve — essentially, how many eggs you have left in the pool.

Reference ranges differ slightly between labs, but a commonly used framework looks like this:

A low result triggers concern because it correlates with fewer retrievable eggs in IVF cycles and an earlier transition toward menopause. But correlation is not destiny. Plenty of women with AMH below 1.0 ng/mL have conceived naturally, and a number of the causes below are addressable.

If you've been told your AMH is low and you want to understand the natural levers available, it helps to first map out what drove it down.

---

The Primary Causes of Low AMH in Women

1. Age-Related Follicular Decline

The most straightforward cause. Women are born with a fixed number of primordial follicles — estimates range from 1 to 2 million at birth, declining to roughly 300,000 by puberty and continuing downward from there. AMH tracks this pool closely. Peak AMH typically occurs between ages 24–26 and then falls steadily. By the mid-thirties, values often drop below 2.0 ng/mL in otherwise healthy women, and this is physiologically normal.

The clinical concern arises when AMH is low relative to chronological age — a 32-year-old with an AMH of 0.4 ng/mL warrants evaluation; a 44-year-old with the same result is less surprising.

2. Premature Ovarian Insufficiency (POI)

POI — formerly called premature ovarian failure — is defined as ovarian dysfunction before age 40, characterized by irregular or absent periods, elevated FSH, and very low AMH. It affects approximately 1 in 100 women under 40 (Webber et al., Human Reproduction 2016; PMID: 26843545). Causes include autoimmune attack on ovarian tissue (particularly in women with thyroid antibodies or Addison's disease), chromosomal abnormalities like Turner syndrome mosaic variants, and prior chemotherapy or pelvic radiation.

POI is the scenario where AMH restoration through lifestyle alone is unlikely; reproductive endocrinology consultation is essential.

3. Endometriosis

Endometriosis is among the most well-documented non-age-related causes of low AMH. Ovarian endometriomas ("chocolate cysts") directly destroy follicle-containing ovarian cortex, and the inflammatory microenvironment further suppresses granulosa cell function. A systematic review found that women with endometriosis had significantly lower AMH than age-matched controls, with endometrioma surgery compounding the loss (Raffi et al., Human Reproduction 2012; PMID: 22258661).

Even without cysts, the chronic peritoneal inflammation of endometriosis appears to reduce ovarian reserve over time, making early diagnosis and management consequential for long-term fertility.

4. Autoimmune and Thyroid Conditions

Thyroid dysfunction — particularly autoimmune thyroiditis (Hashimoto's) — is tightly linked to ovarian function. Women with elevated thyroid peroxidase (TPO) antibodies show lower AMH independent of TSH levels, suggesting that the autoimmune process itself, not just overt hypothyroidism, impairs ovarian reserve (Poppe et al., Clinical Endocrinology 2008; PMID: 17854390).

If your TSH has been trending low or high, that thyroid-ovarian connection deserves attention. More broadly, any autoimmune condition that generates systemic inflammation can accelerate follicle atresia.

5. Oxidative Stress and Chronic Inflammation

Granulosa cells are particularly sensitive to reactive oxygen species (ROS). High oxidative burden — from poor diet, smoking, sleep deprivation, or metabolic dysfunction — accelerates follicular death. Markers like high-sensitivity CRP correlate inversely with AMH in cross-sectional data, meaning the more inflamed the systemic environment, the lower ovarian reserve tends to run.

This is also why chronically elevated CRP matters beyond cardiovascular risk — the inflammatory load touches hormonal systems in ways standard checkups often miss.

6. Nutritional Deficiencies

Several specific micronutrient gaps have been associated with lower AMH or accelerated follicular decline:

Vitamin D: A randomized controlled trial found that Vitamin D supplementation over 3 months increased AMH in women with PCOS who were Vitamin D-deficient (Irani et al., European Journal of Obstetrics & Gynecology 2017; PMID: 28088623). Vitamin D receptors are expressed on granulosa cells, and deficiency impairs their function.

Folate: Adequate folate status supports DNA repair in rapidly dividing follicular cells. Low folate is associated with poor oocyte quality in IVF outcomes data, though direct AMH studies are limited.

Zinc: Zinc is critical to folliculogenesis and granulosa cell proliferation. Low zinc in women is more common than appreciated, particularly in those with high stress loads or plant-dominant diets, and zinc depletion impairs the ovarian steroidogenic pathway.

Coenzyme Q10: Mitochondrial function declines in aging oocytes, and CoQ10 is the key electron carrier in that process. Preliminary evidence suggests supplementation may support oocyte quality, particularly in women over 35, though robust AMH-specific RCTs are still emerging.

Omega-3 fatty acids: Anti-inflammatory EPA and DHA help reduce the peritoneal inflammatory burden that harms follicle survival, and higher omega-3 intake is associated with slower age-related AMH decline in epidemiological studies.

7. Prior Ovarian Surgery

Any surgical procedure on the ovary — cystectomy, wedge resection for PCOS, or oophorectomy — carries risk of inadvertently removing healthy ovarian cortex containing primordial follicles. This is irreversible and accounts for a meaningful proportion of unexpectedly low AMH in women with a surgical history.

8. Chemotherapy and Pelvic Radiation

Gonadotoxic chemotherapy agents, particularly alkylating agents like cyclophosphamide, are among the most potent causes of iatrogenic ovarian insufficiency. AMH often drops sharply during treatment and may partially recover, though the extent depends on the agent, dose, and the woman's age at treatment. Fertility preservation (egg/embryo freezing) before gonadotoxic therapy is strongly recommended.

9. Genetic Factors

Fragile X premutation carriers (FMR1 gene) have a significantly elevated risk of POI and low AMH. Turner syndrome mosaicism, BMP15 gene variants, and other chromosomal factors can also reduce ovarian reserve from early adulthood. Genetic karyotyping and FMR1 screening are reasonable when AMH is low in a woman under 35 without an obvious explanation.

---

Does Stress Directly Lower AMH?

This is a question many women ask after a stressful period coincides with a low AMH result. The evidence is indirect but plausible: chronic hypothalamic-pituitary-adrenal (HPA) axis activation elevates cortisol, which suppresses GnRH pulsatility and downstream LH/FSH signaling. Over time, disrupted gonadotropin signaling may reduce granulosa cell AMH secretion independently of actual follicle loss.

Moreover, cortisol-driven sleep disruption increases oxidative stress, which circles back to follicular damage. Women who present with fatigue, low libido, and poor recovery alongside a declining AMH should be evaluated for adrenal dysregulation as a contributing factor, not just a downstream effect.

---

What Causes a Sudden Drop in AMH?

AMH isn't truly stable — studies show intra-individual variation of 10–20% between measurements, and seasonal variation has been reported. A single low value deserves confirmation with a repeat test. That said, genuinely rapid decline can occur with:

• A new diagnosis of endometriosis or worsening cyst burden
• Ovarian surgery
• Initiation of gonadotoxic therapy
• Acute severe illness with oxidative and inflammatory surge
• Significant vitamin D depletion over winter months

If your AMH dropped more than expected between tests, a thorough review of what changed in that interval — medications, surgeries, illness, nutritional status — is the starting point before concluding the decline is irreversible.

---

What This Means for Your Formula

Ones uses blood work, wearable data, and health history to build personalized supplement formulas, and ovarian reserve support is one of several hormone-adjacent targets in its catalog. Based on the evidence reviewed above, here are the ingredients most relevant to women with low AMH:

Vitamin D3 + K2 (MK-7): Ones includes D3 paired with K2 in MK-7 form to support proper calcium partitioning alongside the ovarian benefits. The Irani 2017 RCT used doses in the 2,000–4,000 IU range for women with demonstrated deficiency — consistent with what Ones calibrates based on a user's baseline 25-OH-D result. Supplementing without knowing your level is less effective, which is why the personalized approach matters here.

Omega-3 (EPA/DHA): Ones includes pharmaceutical-grade omega-3s with meaningful EPA and DHA content, targeting the anti-inflammatory pathway relevant to both endometriosis-related follicular damage and age-related oxidative stress in ovarian tissue.

Zinc: For women with confirmed low zinc — which tends to be underdiagnosed — Ones includes zinc at doses calibrated to repletion, not just maintenance. Zinc's role in granulosa cell function and folliculogenesis makes it particularly relevant here.

None of these ingredients will reverse structural ovarian loss from surgery or genetic POI — and Ones is transparent about that. But for women whose low AMH reflects nutritional burden, inflammation, or oxidative stress, addressing those gaps with precision is more rational than a blanket multivitamin.

---

Key Takeaways

• Low AMH most commonly reflects reduced ovarian reserve, but causes range from age and genetics to modifiable factors like nutrition, oxidative stress, and thyroid autoimmunity.
• Endometriosis, prior ovarian surgery, and gonadotoxic chemotherapy are among the most impactful non-age causes and warrant specialist evaluation.
• Vitamin D deficiency, low zinc, inadequate omega-3 intake, and elevated systemic inflammation are the most evidence-supported nutritional contributors to suppressed AMH.
• A single low AMH reading should be confirmed with a repeat test — intra-individual variation of 10–20% is normal, and values fluctuate with season and stress.
• Women with AMH below age-expected norms before 40 should be evaluated for thyroid antibodies, FMR1 premutation, and karyotype abnormalities before assuming idiopathic decline.
• Targeted supplementation based on confirmed deficiencies — not generic protocols — is the rational approach to supporting whatever ovarian reserve remains.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider or reproductive endocrinologist for evaluation and treatment of low AMH or fertility concerns.